Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

594.00INR
22 Feb 2018
Change (% chg)

Rs6.00 (+1.02%)
Prev Close
Rs588.00
Open
Rs591.80
Day's High
Rs605.00
Day's Low
Rs590.00
Volume
1,576,584
Avg. Vol
1,539,111
52-wk High
Rs663.40
52-wk Low
Rs480.20

Select another date:

Thu, Feb 8 2018

Photo

Sensex snaps seven-session losing streak, rises nearly 1 percent

Indian shares rose nearly 1 percent on Thursday, snapping seven sessions of fall, as market heavyweights such as Infosys Ltd and Housing Development Finance Corp helped the indexes end their longest spell of losses since September.

Indian shares gain over 1 pct after 7 days of falls

Feb 8 Indian shares rose more than 1 percent on Thursday after seven consecutive sessions of declines, as market heavyweights such as Infosys recovered and as drug maker Cipla gained on solid earnings.

BUZZ-India's Cipla surges after third-quarter results

** Shares of Cipla Ltd surge as much as 6.85 pct to 608.2 rupees, in their biggest intraday pct gain since Nov 2016

Cipla third-quarter profit rises, but below estimates

Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates.

UPDATE 1-India's Cipla Q3 profit rises, but below estimates

Feb 7 Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates.

BRIEF-Cipla Says Key Performance Metrics Inline With Co's Internal Targets

* SAYS KEY PERFORMANCE METRICS LOOK HEALTHY AND ARE INLINE WITH CO'S INTERNAL TARGETS Source text - http://bit.ly/2BhN3M6 Further company coverage:

India's Cipla Q3 profit rises about 7 pct

Feb 7 Cipla Ltd, India's fourth-largest drugmaker by revenue, posted an about 7 percent rise in third-quarter net profit on Wednesday, but missed analysts' estimates.

BRIEF-India's Cipla Dec-Qtr Consol Profit Up 7 Pct

* DEC QUARTER CONSOL NET PROFIT 4.01 BILLION RUPEES VERSUS PROFIT OF 3.75 BILLION RUPEES LAST YEAR

BRIEF-India's Cipla Gets U.S. FDA Nod For Generic Viread Tablets

* GETS ANDA FOR TENOFOVIR DISOPROXIL FUMARATE TABLETS FROM U.S. FDA Source text - http://bit.ly/2DW6lbS Further company coverage:

BRIEF-Kiadis Pharma Proposes Subhanu Saxena, Former Cipla CEO, As New Supervisory Board Member

* KIADIS PHARMA PROPOSES FORMER CIPLA CEO SUBHANU SAXENA AS NEW SUPERVISORY BOARD MEMBER

Select another date: